Precision Oncology Clinical Trials: A Systematic Review of Phase II Clinical Trials with Biomarker-Driven, Adaptive Design

Overview

Journal Cancer Res Treat

Specialty Oncology

Date 2024 May 10

PMID 38726510

Authors

Hyerim Ha

Hee Yeon Lee

Jee Hyun Kim

Do Yeun Kim

Ho Jung An

SeungJin Bae

Hye-Sung Park

Jin Hyoung Kang

Affiliations

Soon will be listed here.

Abstract

Novel clinical trial designs are conducted in the precision medicine era. This study aimed to evaluate biomarker-driven, adaptive phase II trials in precision oncology, focusing on infrastructure, efficacy, and safety. We systematically reviewed and analyzed the target studies. EMBASE and PubMed searches from 2015 to 2023 generated 29 eligible trials. Data extraction included infrastructure, biomarker screening methodologies, efficacy, and safety profiles. Government agencies, cancer hospitals, and academic societies with accumulated experiences led investigator-initiated precision oncology clinical trials (IIPOCTs), which later guided sponsor-initiated precision oncology clinical trials (SIPOCTs). Most SIPOCTs were international studies with basket design. IIPOCTs primarily used the central laboratory for biomarker screening, but SIPOCTs used both central and local laboratories. Most of the studies adapted next-generation sequencing and/or immunohistochemistry for biomarker screening. Fifteen studies included an independent central review committee for outcome investigation. Efficacy assessments predominantly featured objective response rate as the primary endpoint, with varying results. Nine eligible studies contributed to the United States Food and Drug Administration's marketing authorization. Safety monitoring was rigorous, but reporting formats lacked uniformity. Health-related quality of life and patient-reported outcomes were described in some protocols but rarely reported. Our results reveal that precision oncology trials with adaptive design rapidly and efficiently evaluate anticancer drugs' efficacy and safety, particularly in specified biomarker-driven cohorts. The evolution from IIPOCT to SIPOCT has facilitated fast regulatory approval, providing valuable insights into the precision oncology landscape.

References

Subbiah V, Kreitman R, Wainberg Z, Cho J, Schellens J, Soria J . Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022; 33(4):406-415. PMC: 9338780. DOI: 10.1016/j.annonc.2021.12.014. View

Seligmann J, Fisher D, Brown L, Adams R, Graham J, Quirke P . Inhibition of WEE1 Is Effective in - and -Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. J Clin Oncol. 2021; 39(33):3705-3715. PMC: 8601321. DOI: 10.1200/JCO.21.01435. View

Geoerger B, Kang H, Yalon-Oren M, Marshall L, Vezina C, Pappo A . Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2019; 21(1):121-133. DOI: 10.1016/S1470-2045(19)30671-0. View

Ahn E, Mangat P, Garrett-Mayer E, Halabi S, Dib E, Haggstrom D . Palbociclib in Patients With Non-Small-Cell Lung Cancer With Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2022; 4:757-766. DOI: 10.1200/PO.20.00037. View

Kasi P . Treatment Holidays for Patients With Metastatic Colorectal Cancer. J Clin Oncol. 2021; 39(33):3656-3659. DOI: 10.1200/JCO.21.01999. View

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

Le Tourneau C, Delord J, Goncalves A, Gavoille C, Dubot C, Isambert N . Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015; 16(13):1324-34. DOI: 10.1016/S1470-2045(15)00188-6. View

de Langen A, Johnson M, Mazieres J, Dingemans A, Mountzios G, Pless M . Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS mutation: a randomised, open-label, phase 3 trial. Lancet. 2023; 401(10378):733-746. DOI: 10.1016/S0140-6736(23)00221-0. View

Baghdadi T, Garrett-Mayer E, Halabi S, Mangat P, Rich P, Ahn E . Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020; 15(6):743-750. DOI: 10.1007/s11523-020-00752-8. View

10.

Yu Z, Wu L, Bunn V, Li Q, Lin J . Evolution of Phase II Oncology Trial Design: from Single Arm to Master Protocol. Ther Innov Regul Sci. 2023; 57(4):823-838. DOI: 10.1007/s43441-023-00500-w. View

11.

Nanda R, Liu M, Yau C, Shatsky R, Pusztai L, Wallace A . Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020; 6(5):676-684. PMC: 7058271. DOI: 10.1001/jamaoncol.2019.6650. View

12.

Willke R, Burke L, Erickson P . Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials. 2004; 25(6):535-52. DOI: 10.1016/j.cct.2004.09.003. View

13.

Fakih M, Kopetz S, Kuboki Y, Kim T, Munster P, Krauss J . Sotorasib for previously treated colorectal cancers with KRAS mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 2021; 23(1):115-124. DOI: 10.1016/S1470-2045(21)00605-7. View

14.

Dziadziuszko R, Krebs M, De Braud F, Siena S, Drilon A, Doebele R . Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2021; 39(11):1253-1263. PMC: 8078299. DOI: 10.1200/JCO.20.03025. View

15.

Rolfo C, Hess L, Jen M, Peterson P, Li X, Liu H . External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer. ESMO Open. 2022; 7(4):100551. PMC: 9434413. DOI: 10.1016/j.esmoop.2022.100551. View

16.

Aggarwal C, Redman M, Lara Jr P, Borghaei H, Hoffman P, Bradley J . SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). J Thorac Oncol. 2019; 14(10):1847-1852. PMC: 6901020. DOI: 10.1016/j.jtho.2019.05.041. View

17.

Nakauma-Gonzalez J, Rijnders M, van Riet J, van der Heijden M, Voortman J, Cuppen E . Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. Eur Urol. 2022; 81(4):331-336. DOI: 10.1016/j.eururo.2022.01.026. View

18.

Fiteni F, Le Ray I, Ousmen A, Isambert N, Anota A, Bonnetain F . Health-related quality of life as an endpoint in oncology phase I trials: a systematic review. BMC Cancer. 2019; 19(1):361. PMC: 6469065. DOI: 10.1186/s12885-019-5579-3. View

19.

Basch E, Reeve B, Mitchell S, Clauser S, Minasian L, Dueck A . Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014; 106(9). PMC: 4200059. DOI: 10.1093/jnci/dju244. View

20.

Schoffski P, Wozniak A, Kasper B, Aamdal S, Leahy M, Rutkowski P . Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'. Ann Oncol. 2017; 29(3):758-765. DOI: 10.1093/annonc/mdx774. View